Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

Rep. Kathleen Rice speaks during a hearing

Rep. Kathleen Rice (D-N.Y.) delivers remarks during a House hearing on June 20, 2019. (Photo: Tom Brenner/Getty Images)

'Call Them Now': Ire Aimed at 3 Democrats Endangering Plan to Lower Drug Prices

"Any politician standing in the way of lower drug prices is on a short path to losing their job."

Jake Johnson

Update:

The House Energy and Commerce Committee on Wednesday failed to adopt Democrats' plan to let Medicare broadly negotiate prescription drug prices after three Democrats—Reps. Kathleen Rice of New York, Kurt Schrader of Oregon, and Scott Peters of California—voted no.

A spokesperson for House Speaker Nancy Pelosi (D-Calif.) signaled in response to the vote that the Democratic leadership will still aim to include the Medicare negotiation proposal in the final budget reconciliation package.

Earlier:

Progressive advocacy groups on Wednesday sought to dial up the pressure on three House Democrats who are opposing a key element of their own party's plan to lower prescription drug prices, potentially imperiling one of the most popular components of the emerging reconciliation package.

"There is no good reason, none, for any member of Congress to block pricing reform."
—Robert Weissman, Public Citizen

Social Security Works, Public Citizen, and other organizations are working to drive calls to the congressional offices of Reps. Kathleen Rice (D-N.Y.), Kurt Schrader (D-Ore.), and Scott Peters (D-Calif.), House Energy and Commerce Committee members who announced Tuesday that they are against allowing Medicare to broadly negotiate prescription drug prices with pharmaceutical companies.

The three Democrats' opposition to the plan—which is resoundingly favored by the U.S. public—left the narrowly divided committee deadlocked as it tried to advance its section of the party's sprawling budget reconciliation bill.

"There is no good reason, none, for any member of Congress to block pricing reform," Robert Weissman, president of Public Citizen, said in a statement. "There is especially no good reason for any Democrat, since voters elected Democrats specifically to deliver on promises to bring down medicine prices. There are, however, many very identifiable, bad reasons for members to side with Big Pharma and against their constituents."

"By overwhelming numbers, Americans demand that Congress take action on drug pricing. It's patently obvious why: 1-in-4 Americans ration their prescriptions because of too high prices and many others suffer to afford the meds they need," Weissman continued. "Reps. Scott Peters, Kurt Schrader, and Kathleen Rice... should stand down—and stand with the American people."

Schrader and Peters are both major beneficiaries of campaign donations from the pharmaceutical industry, which on Wednesday announced the launch of a seven-figure ad blitz against House Democrats' drug pricing plan—a key component of the party's effort to cut sky-high U.S. medicine costs and finance an expansion of Medicare.

"We won't let a few bought and paid for politicians stop the overwhelming will of the people."
—Alex Lawson, Social Security Works

An alternative proposal put forth by Schrader, Peters, Rice, and two other House Democrats would only allow the federal government to negotiate prices on a narrow subset of prescription drugs in Medicare Part B that currently have no competition.

As The American Prospect's David Dayen noted on Wednesday, "This preserves the patent monopolies that keep drug prices exorbitantly high in the United States, since there is no current check on costs."

"Restricting negotiation to off-patent drugs and restricting the inflation cap to Medicare just allows drug companies to keep excess profits," Dayen added. "It also reduces the amount of money available to offset spending in the bill."

There was little indication as of Wednesday afternoon that the three conservative Democrats intend to back down. Dayen emphasized that "the standoff does not mean that drug price reform is finished," pointing out that "the Budget Committee can always fit it back in with a 'manager's amendment'" if Energy and Commerce fails to approve the plan.

But such a maneuver would likely ensure that Schrader, Peters, and Rice oppose the final reconciliation package, leaving House Democrats without any more votes to spare.

Given the overwhelming popularity of Democrats' drug price negotiation plan in Rice's district, progressives have focused much of their pressure campaign on urging her to flip. Rice, who has received little campaign cash from Big Pharma relative to Schrader and Peters, was chosen for a spot on the House Energy and Commerce Committee over progressive Rep. Alexandria Ocasio-Cortez (D-N.Y.) last December.

Alex Lawson, executive director of Social Security Works, said in a statement Wednesday that "it is disgusting when politicians who supported Medicare negotiation in the past switch their votes in exchange for pharma cash."

"But we won't let a few bought and paid for politicians stop the overwhelming will of the people," Lawson added. "We are going to get Medicare negotiation into the Build Back Better package, we are going to pass it into law, and we are going to lower drug prices for everyone. Any politician standing in the way of lower drug prices is on a short path to losing their job."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.

One Year In, Biden Fails to Boost C- Grade on Environment

The Center for Biological Diversity Action Fund assessment indicates the administration's action to deliver on environmental promises "desperately needs improvement."

Jessica Corbett ·


'A No-Brainer': Lawmakers Urge Pelosi to Hold Vote on Stock Trading Ban

"Perhaps this means some of our colleagues will miss out on lucrative investment opportunities," said House members in a bipartisan letter. "We don't care."

Jessica Corbett ·


Virginia Schools Sue Youngkin Mandate Making Masks Optional

The Republican governor wants to allow parents to decide whether their children should wear masks to school to mitigate Covid-19 transmission—guidance at least 58 school districts have no plans to follow.

Julia Conley ·


US Puts Troops on Standby as War Tensions Over Ukraine Mount

The U.K. threatens "lightning war" as military forces mobilize in eastern Europe.

Andrea Germanos ·


Advocacy Group Urges Pfizer to Combat Paxlovid Inequality

"Help end the pandemic this year around the world," one advocate told Pfizer. "Not just in a handful of rich countries."

Kenny Stancil ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo